Heparin, Low-Molecular-Weight
-
Subject Areas on Research
-
A marriage of enhancement: fibrinolysis and conjunctive therapy.
-
A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.
-
A perioperative strategy for the placement of a thoracic epidural catheter in a pediatric patient on high-dose enoxaprin.
-
A quality improvement initiative to reduce venous thromboembolism on a gynecologic oncology service.
-
A rare cutaneous manifestation of hemorrhagic bullae to low-molecular-weight heparin and fondaparinux: report of two cases.
-
A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
-
A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience.
-
Advances in the approach to acute coronary syndromes.
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.
-
Anticoagulant therapy during cardiopulmonary bypass.
-
Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
-
Anticoagulant therapy in unstable angina.
-
Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
-
Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study.
-
Anticoagulation therapy.
-
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
-
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
-
Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
-
Bridging Anticoagulation in Patients with Atrial Fibrillation.
-
Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.
-
Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.
-
Coagulation abnormalities and thrombosis in patients with COVID-19.
-
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
-
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
-
Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery.
-
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction.
-
Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial.
-
Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials.
-
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
-
Early Chemoprophylaxis Against Venous Thromboembolism in Patients With Traumatic Brain Injury.
-
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
-
Economics of low-molecular weight heparins.
-
Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.
-
Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.
-
Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group.
-
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
-
Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
-
Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
-
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
-
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study.
-
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events.
-
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
-
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE).
-
Future alternatives to heparin: low-molecular-weight heparin and hirudin.
-
Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.
-
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
-
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
-
Heparins: their established role in acute coronary syndromes and perspectives in atrial fibrillation.
-
Hospital variability in use of anticoagulant strategies during acute myocardial infarction treated with an early invasive strategy.
-
ISTH guidelines for antithrombotic treatment in COVID-19.
-
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.
-
Improved microsurgical anastomotic patency with low molecular weight heparin.
-
Influence of clinical trial participation on subsequent antithrombin use.
-
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes.
-
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
-
Issues in the utilization of low molecular weight heparins.
-
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
-
Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial.
-
Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial.
-
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
-
Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves.
-
Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
-
Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
-
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
-
Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis.
-
Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery.
-
Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.
-
Off-the-shelf, heparinized small diameter vascular graft limits acute thrombogenicity in a porcine model.
-
PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses.
-
Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin.
-
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
-
Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry).
-
Perioperative management of patients on chronic antithrombotic therapy.
-
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
-
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
-
Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims.
-
Poor Adherence to Risk Stratification Guidelines Results in Overuse of Venous Thromboembolism Prophylaxis in Hospitalized Older Adults.
-
Portal vein thrombosis: an unexpected finding in a 28-year-old male with abdominal pain.
-
Post-operative pharmacologic thromboprophylaxis after major hepatectomy: does peripheral venous thromboembolism prevention outweigh bleeding risks?
-
Potassium homeostasis in patients receiving prophylactic dose enoxaparin therapy.
-
Practice bulletin no. 123: thromboembolism in pregnancy.
-
Preclinical differentiation of low molecular weight heparins.
-
Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial.
-
Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery.
-
Prevention and management of venous thromboembolism in pregnancy.
-
Prevention and treatment of venous thromboembolism in pregnancy.
-
Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty.
-
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
-
Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.
-
Pursuing progress in acute coronary syndromes.
-
Recombinant Human Antithrombin in Pregnant Patients with Hereditary Antithrombin Deficiency: Integrated Analysis of Clinical Data.
-
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
-
Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options.
-
Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007.
-
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : V
enous thromboembolism prophylA
xis after gynecoL
ogical pE
lvic cancer surgery with RI
varoxaban versus enoxA
parin (VALERIA trial).
-
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
-
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
-
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
-
Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.
-
Stroke Care during the COVID-19 Pandemic: International Expert Panel Review.
-
Successful Management of Catastrophic Thrombotic Storm in a Young Boy: A Case Report From Northern India.
-
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale.
-
The management of Cesarean delivery in a parturient with paroxysmal nocturnal hemoglobinuria complicated by severe preeclampsia.
-
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
-
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
-
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
-
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
-
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.
-
Thromboprophylaxis for orthopedic surgery; An updated meta-analysis.
-
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.
-
Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.
-
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
-
To bridge or not to bridge: these are the questions.
-
Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy.
-
Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes.
-
Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity.
-
Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines).
-
Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia.
-
Venous thromboembolism debate in joint arthroplasty.
-
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
-
When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events.
-
Keywords of People
-
Alexander, John Hunter Peel,
Professor of Medicine,
Medicine, Cardiology
-
Arepally, Gowthami Morey,
Professor of Medicine,
Pathology
-
O'Connor, Christopher Michael,
Richard Sean Stack, M.D. Distinguished Professor,
Medicine, Clinical Pharmacology